description
In unstressed cells, TP53 (p53) has a short half-life as it undergoes rapid ubiquitination and proteasome-mediated degradation. The E3 ubiquitin ligase MDM2, which is a transcriptional target of TP53, plays the main role in TP53 protein down-regulation (Wu et al. 1993). MDM2 forms homodimers and homo-oligomers, but also functions as a heterodimer/hetero-oligomer with MDM4 (MDMX) (Sharp et al. 1999, Cheng et al. 2011, Huang et al. 2011, Pant et al. 2011). The heterodimers of MDM2 and MDM4 may be especially important for downregulation of TP53 during embryonic development (Pant et al. 2011).The nuclear localization of MDM2 is positively regulated by AKT- or SGK1- mediated phosphorylation (Mayo and Donner 2001, Zhou et al. 2001, Amato et al. 2009, Lyo et al. 2010). Phosphorylation of MDM2 by CDK1 or CDK2 decreases affinity of MDM2 for TP53 (Zhang and Prives 2001). ATM and CHEK2 kinases, activated by double strand DNA breaks, phosphorylate TP53, reducing its affinity for MDM2 (Banin et al. 1998, Canman et al. 1998, Khanna et al. 1998, Chehab et al. 1999, Chehab et al. 2000). At the same time, ATM phosphorylates MDM2, preventing MDM2 dimerization (Cheng et al. 2009, Cheng et al. 2011). Both ATM and CHEK2 phosphorylate MDM4, triggering MDM2-mediated ubiquitination of MDM4 (Chen et al. 2005, Pereg et al. 2005). Cyclin G1 (CCNG1), transcriptionally induced by TP53, targets the PP2A phosphatase complex to MDM2, resulting in dephosphorylation of MDM2 at specific sites, which can have either a positive or a negative impact on MDM2 function (Okamoto et al. 2002).In contrast to MDM2, E3 ubiquitin ligases RNF34 (CARP1) and RFFL (CARP2) can ubiquitinate phosphorylated TP53 (Yang et al. 2007).In addition to ubiquitinating MDM4 (Pereg et al. 2005), MDM2 can also undergo auto-ubiquitination (Fang et al. 2000). MDM2 and MDM4 can be deubiquitinated by the ubiquitin protease USP2 (Stevenson et al. 2007, Allende-Vega et al. 2010). The ubiquitin protease USP7 can deubiquitinate TP53, but in the presence of DAXX deubiquitinates MDM2 (Li et al. 2002, Sheng et al. 2006, Tang et al. 2006).The tumor suppressor p14-ARF, expressed from the CDKN2A gene in response to oncogenic or oxidative stress, forms a tripartite complex with MDM2 and TP53, sequesters MDM2 from TP53, and thus prevents TP53 degradation (Zhang et al. 1998, Parisi et al. 2002, Voncken et al. 2005).For review of this topic, please refer to Kruse and Gu 2009

external resources
NCBI:1383079
REACTOME:R-HSA-6804757
PUBMED:21730132
PUBMED:10570149
PUBMED:15563468
PUBMED:16845383
PUBMED:11923872
PUBMED:11883935
PUBMED:17290220
PUBMED:17121812
PUBMED:10673500
PUBMED:9843217
PUBMED:9529249
PUBMED:21730163
PUBMED:11715018
PUBMED:9733514
PUBMED:19838211
PUBMED:10608892
PUBMED:16474402
PUBMED:19450511
PUBMED:16163388
PUBMED:10722742
PUBMED:21986495
PUBMED:15788536
PUBMED:19816404
PUBMED:11359766
PUBMED:11504915
PUBMED:9733515
PUBMED:19756449
PUBMED:11983168
PUBMED:8319905
PUBMED:20438709

genes
AKT1 , AKT2 , ATM , CCNA2 , CCNG1 , CDK1 , CDK2 , CDKN2A , DAXX , MTOR , MDM2 , MDM4 , PDPK1 , PPP2CA , PPP2CB , PPP2R1A , PPP2R1B , PPP2R5C , RPS27A , SGK1 , TP53 , UBA52 , UBB , UBC , USP7 , CCNA1 , USP2 , AKT3 , CHEK2 , PRR5 , MLST8 , MAPKAP1 , RNF34 , RFFL , RICTOR ,